Feeds › FDA approvals and clearances
FDA approvals and clearances
New drugs and biologics the FDA approved, and the devices it cleared or approved, from openFDA, with the public companies among the applicants.
About this data
- What it is
- The FDA publishes its decisions on drugs and medical devices through openFDA. We list approved drug applications and the changes approved to them, 510(k) clearances of devices and premarket approvals (PMA) of higher-risk devices, and match the applicant to a public company when the name lines up. The page opens on new brand-name drugs and biologics: the first approval of a new drug application (NDA) or biologics license application (BLA).
- Who files it
- The FDA decides; openFDA publishes the FDA's records. The applicant is the company named in the FDA's record for the application.
- How current
- We check openFDA every day. The FDA refreshes its files on its own schedule, and a decision can appear days to weeks after its date, so the latest approvals may show up late.
- Terms
- openFDAopenFDA is the FDA's public data service. It publishes the FDA's own records of drug approvals and device decisions. openFDA asks users not to imply that the FDA endorses their product or service: this site is not endorsed by or affiliated with the FDA.NDA and BLAA new drug application (NDA) asks the FDA to approve a drug made from chemicals. A biologics license application (BLA) asks for a biologic, such as an antibody or a vaccine. The first approval is the original.supplementA later approved change to a drug that is already on the market: a new use, a new dose, a label change or a manufacturing change. Many supplements are minor.generic drugsA generic drug (an ANDA, or abbreviated new drug application) is approved because it matches a drug already on the market. Generics are made by many companies, most of which are not public.510(k)A device maker shows the FDA that its device is substantially equivalent to one already sold. The FDA clears it, which is a lighter review than an approval.PMAPremarket approval: the FDA's strictest review, for higher-risk devices. The maker must show the device is safe and effective.company matchWe match the applicant's name to a public company automatically, and by hand for the large drugmakers. Most applicants, such as generic makers and private device makers, do not match, and a subsidiary or a differently spelled name can be missed.
- Worth knowing
- This is a record of decisions already made. It is not a calendar of coming decisions: a drug under review does not appear, and we show no review dates. openFDA asks users not to imply that the FDA endorses their product or service: this page is not endorsed by or affiliated with the FDA, and the FDA makes no warranty about the data. It is not for medical decisions. Most applicants, such as generic makers and private device makers, do not match a public company, and a subsidiary or a differently spelled name can be missed, so a row with no ticker may still belong to one. A clearance is not an approval, and many approved supplements are minor.
- Not to be confused with
- Clinical trial updates: what sponsors report about their studies, not what the FDA decided.
All of this comes from openFDA, the FDA's public data service. This site is not endorsed by or affiliated with the FDA.
Source and freshness · Information, not investment advice (disclaimer).
FDA decisions per day, last 30 days
Brand-name drugs and biologics, with supplements Device clearances and approvals
By the FDA's decision date. Generic drugs are left out. The FDA's files can lag a decision by days to weeks, so the most recent days fill in later.
Latest FDA decisions
Showing: ticker NVO · Everything
| Decided | Product | ApplicantWe match the applicant's name to a public company automatically, and by hand for the large drugmakers. Most applicants, such as generic makers and private device makers, do not match, and a subsidiary or a differently spelled name can be missed. | DecisionA new drug application (NDA) asks the FDA to approve a drug made from chemicals. A biologics license application (BLA) asks for a biologic, such as an antibody or a vaccine. The first approval is the original. A device maker shows the FDA that its device is substantially equivalent to one already sold. The FDA clears it, which is a lighter review than an approval. Premarket approval: the FDA's strictest review, for higher-risk devices. The maker must show the device is safe and effective. | FDA page |
|---|---|---|---|---|
| Oct 23, 2026 | AWIQLI FLEXTOUCH INSULIN ICODEC | NVO Novo Nordisk Inc | Biologic (BLA), supplement Efficacy | BLA761326 ↗ |
| Mar 26, 2026 | AWIQLI FLEXTOUCH INSULIN ICODEC | NVO Novo Nordisk Inc | Biologic (BLA) Type 1 - New Molecular Entity | BLA761326 ↗ |
| Feb 27, 2026 | SOGROYA SOMAPACITAN-BECO | NVO Novo Nordisk Inc | Biologic (BLA), supplement Efficacy | BLA761156 ↗ Letter or label ↗ |
| Feb 27, 2026 | SOGROYA SOMAPACITAN-BECO | NVO Novo Nordisk Inc | Biologic (BLA), supplement Efficacy | BLA761156 ↗ Letter or label ↗ |
| Feb 27, 2026 | SOGROYA SOMAPACITAN-BECO | NVO Novo Nordisk Inc | Biologic (BLA), supplement Efficacy | BLA761156 ↗ Letter or label ↗ |
| Oct 14, 2025 | LIRAGLUTIDE, VICTOZA LIRAGLUTIDE | NVO Novo Nordisk Inc | New drug (NDA), supplement Labeling | NDA022341 ↗ |
| Jul 31, 2025 | ALHEMO CONCIZUMAB | NVO Novo Nordisk Inc | Biologic (BLA) Type 9 - New indication submitted as di… | BLA761428 ↗ |
| Jul 31, 2025 | ALHEMO CONCIZUMAB-MTCI | NVO Novo Nordisk Inc | Biologic (BLA), supplement Labeling | BLA761315 ↗ |
| Jul 9, 2025 | SOGROYA SOMAPACITAN-BECO | NVO Novo Nordisk Inc | Biologic (BLA), supplement Labeling | BLA761156 ↗ |
| Jul 9, 2025 | NORDITROPIN SOMATROPIN | NVO Novo Nordisk Inc | Biologic (BLA), supplement Labeling | BLA021148 ↗ |
| May 28, 2025 | LIRAGLUTIDE, VICTOZA LIRAGLUTIDE | NVO Novo Nordisk Inc | New drug (NDA), supplement Labeling | NDA022341 ↗ Letter or label ↗ |
| May 2, 2025 | ALHEMO CONCIZUMAB-MTCI | NVO Novo Nordisk Inc | Biologic (BLA), supplement Labeling | BLA761315 ↗ |
| Feb 12, 2025 | LIRAGLUTIDE, VICTOZA LIRAGLUTIDE | NVO Novo Nordisk Inc | New drug (NDA), supplement Labeling | NDA022341 ↗ |
| Jan 31, 2025 | SOGROYA SOMAPACITAN-BECO | NVO Novo Nordisk Inc | Biologic (BLA), supplement Labeling | BLA761156 ↗ |
| Jan 31, 2025 | NORDITROPIN SOMATROPIN | NVO Novo Nordisk Inc | Biologic (BLA), supplement Labeling | BLA021148 ↗ |
| Jan 31, 2025 | NORDITROPIN SOMATROPIN | NVO Novo Nordisk Inc | Biologic (BLA), supplement Labeling | BLA021148 ↗ |
| Dec 20, 2024 | ALHEMO CONCIZUMAB-MTCI | NVO Novo Nordisk Inc | Biologic (BLA) Type 1 - New Molecular Entity | BLA761315 ↗ |
| Nov 1, 2024 | LIRAGLUTIDE, VICTOZA LIRAGLUTIDE | NVO Novo Nordisk Inc | New drug (NDA), supplement Labeling | NDA022341 ↗ |
| Feb 15, 2024 | VAGIFEM ESTRADIOL | NVO Novo Nordisk Inc | New drug (NDA), supplement Labeling | NDA020908 ↗ |
| Dec 4, 2023 | VAGIFEM ESTRADIOL | NVO Novo Nordisk Inc | New drug (NDA), supplement Labeling | NDA020908 ↗ |
| Aug 25, 2023 | NovoFine® Plus | NVO Novo Nordisk, Inc. | Device clearance (510(k)) Special | K231255 ↗ |
| Jul 5, 2023 | LIRAGLUTIDE, VICTOZA LIRAGLUTIDE | NVO Novo Nordisk Inc | New drug (NDA), supplement Labeling | NDA022341 ↗ |
| Apr 28, 2023 | SOGROYA SOMAPACITAN-BECO | NVO Novo Nordisk Inc | Biologic (BLA), supplement Efficacy | BLA761156 ↗ |
| Feb 28, 2023 | INSULIN ASPART PROTAMINE AND INSULIN ASPART MIX 70/30 INSULIN ASPART PROTAMINE RECOMBINANT; INSULIN ASPART RECOMB… | NVO Novo Nordisk Inc | Biologic (BLA), supplement Labeling | BLA021172 ↗ |
| Feb 28, 2023 | INSULIN DILUTING MEDIUM FOR NOVOLOG, NOVOLOG, INSULIN ASPART INSULIN ASPART RECOMBINANT | NVO Novo Nordisk Inc | Biologic (BLA), supplement Labeling | BLA020986 ↗ |
| Dec 8, 2022 | LEVEMIR FLEXTOUCH, LEVEMIR INNOLET, LEVEMIR, LEVEMIR PENFIL… INSULIN DETEMIR RECOMBINANT | NVO Novo Nordisk Inc | Biologic (BLA), supplement Labeling | BLA021536 ↗ |
| Nov 23, 2022 | NOVOLIN 70/30 INSULIN RECOMBINANT HUMAN; INSULIN SUSP ISOPHANE RECOMBINAN… | NVO Novo Nordisk Inc | Biologic (BLA), supplement Labeling | BLA019991 ↗ |
| Nov 23, 2022 | NOVOLIN N INSULIN SUSP ISOPHANE RECOMBINANT HUMAN | NVO Novo Nordisk Inc | Biologic (BLA), supplement Labeling | BLA019959 ↗ |
| Nov 23, 2022 | NOVOLIN R INSULIN RECOMBINANT HUMAN | NVO Novo Nordisk Inc | Biologic (BLA), supplement Labeling | BLA019938 ↗ |
| Sep 29, 2022 | VAGIFEM ESTRADIOL | NVO Novo Nordisk Inc | New drug (NDA), supplement Labeling | NDA020908 ↗ |
| Jul 1, 2022 | LEVEMIR FLEXTOUCH, LEVEMIR INNOLET, LEVEMIR, LEVEMIR PENFIL… INSULIN DETEMIR RECOMBINANT | NVO Novo Nordisk Inc | Biologic (BLA), supplement Labeling | BLA021536 ↗ |
| Jun 10, 2022 | LIRAGLUTIDE, VICTOZA LIRAGLUTIDE | NVO Novo Nordisk Inc | New drug (NDA), supplement Labeling | NDA022341 ↗ Letter or label ↗ |
| Jun 10, 2022 | LIRAGLUTIDE, VICTOZA LIRAGLUTIDE | NVO Novo Nordisk Inc | New drug (NDA), supplement Labeling | NDA022341 ↗ Letter or label ↗ |
| Oct 22, 2021 | INSULIN DILUTING MEDIUM FOR NOVOLOG, NOVOLOG, INSULIN ASPART INSULIN ASPART RECOMBINANT | NVO Novo Nordisk Inc | Biologic (BLA), supplement Manufacturing (CMC) | BLA020986 ↗ |
| Oct 1, 2021 | SOGROYA SOMAPACITAN-BECO | NVO Novo Nordisk Inc | Biologic (BLA), supplement Labeling | BLA761156 ↗ Letter or label ↗ |
| Oct 1, 2021 | SOGROYA SOMAPACITAN-BECO | NVO Novo Nordisk Inc | Biologic (BLA), supplement Labeling | BLA761156 ↗ Letter or label ↗ |
| Jul 20, 2021 | GLUCAGEN GLUCAGON HYDROCHLORIDE | NVO Novo Nordisk | New drug (NDA), supplement Labeling | NDA020918 ↗ Letter or label ↗ |
| Jun 23, 2021 | NovoFine | NVO Novo Nordisk, Inc. | Device clearance (510(k)) Traditional | K210258 ↗ |
| Apr 28, 2021 | INSULIN ASPART PROTAMINE AND INSULIN ASPART MIX 70/30 INSULIN ASPART PROTAMINE RECOMBINANT; INSULIN ASPART RECOMB… | NVO Novo Nordisk Inc | Biologic (BLA), supplement Labeling | BLA021172 ↗ Letter or label ↗ |
| Mar 23, 2021 | INSULIN DILUTING MEDIUM FOR NOVOLOG, NOVOLOG, INSULIN ASPART INSULIN ASPART RECOMBINANT | NVO Novo Nordisk Inc | Biologic (BLA), supplement Labeling | BLA020986 ↗ Letter or label ↗ |
| Mar 11, 2021 | GLUCAGEN GLUCAGON HYDROCHLORIDE | NVO Novo Nordisk | New drug (NDA), supplement Labeling | NDA020918 ↗ Letter or label ↗ |
| Dec 19, 2020 | NovoFine Plus 32G Tip x 4 mm | NVO Novo Nordisk, Inc. | Device clearance (510(k)) Traditional | K202005 ↗ |
| Nov 20, 2020 | LIRAGLUTIDE, VICTOZA LIRAGLUTIDE | NVO Novo Nordisk Inc | New drug (NDA), supplement Labeling | NDA022341 ↗ Letter or label ↗ |
| Sep 3, 2020 | GLUCAGEN GLUCAGON HYDROCHLORIDE | NVO Novo Nordisk | New drug (NDA), supplement Labeling | NDA020918 ↗ Letter or label ↗ |
| Aug 28, 2020 | SOGROYA SOMAPACITAN-BECO | NVO Novo Nordisk Inc | Biologic (BLA) Type 1 - New Molecular Entity | BLA761156 ↗ Letter or label ↗ |
| Aug 5, 2020 | LIRAGLUTIDE, VICTOZA LIRAGLUTIDE | NVO Novo Nordisk Inc | New drug (NDA), supplement Labeling | NDA022341 ↗ Letter or label ↗ |
| Mar 9, 2020 | NORDITROPIN SOMATROPIN | NVO Novo Nordisk Inc | Biologic (BLA), supplement Labeling | BLA021148 ↗ Letter or label ↗ |
| Jan 16, 2020 | RYBELSUS SEMAGLUTIDE | NVO Novo Nordisk Inc | New drug (NDA) Type 9 - New Indication Submitted as Di… | NDA213182 ↗ Letter or label ↗ |
| Dec 27, 2019 | LEVEMIR FLEXTOUCH, LEVEMIR INNOLET, LEVEMIR, LEVEMIR PENFIL… INSULIN DETEMIR RECOMBINANT | NVO Novo Nordisk Inc | Biologic (BLA), supplement Labeling | BLA021536 ↗ Letter or label ↗ |
| Nov 15, 2019 | NOVOLOG MIX 50/50 INSULIN ASPART PROTAMINE RECOMBINANT; INSULIN ASPART RECOMB… | NVO Novo Nordisk Inc | Biologic (BLA), supplement Labeling | BLA021810 ↗ Letter or label ↗ |
The newest 50 items, most recent first. Each row links to the FDA's page for the application, clearance or approval. Updated Nov 15, 2026, 7:56 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates